A bumper crop of orphan drugs from the likes of Amicus, Kyowa Kirin, Eusa and Biogen dominates this year’s UK Prix Galien shortlist as biotech firms and specialist pharma companies cement t
The prestigious UK Prix Galien Awards has added medical technology to its roster for the first time, recognising the burgeoning innovation in the field.
Real-world evidence is continuing to climb up the agenda for health systems and the pharma industry, and this trend was confirmed last night at the UK Prix Galien awards.
AstraZeneca, Bristol-Myers Squibb and Boehringer Ingelheim will be among the finalists for the 2016 UK Prix Galien Awards, which celebrate the most innovative products in pharma.
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas